Supernus soars on Indivior merger, Q2 revenue beat
03/08/2026 12:39
BUZZ-Supernus soars on Indivior merger, Q2 revenue beat ** Supernus Pharmaceuticals' shares SUPN.O rise 16.5% to $52 premarket
** Co to merge with Indivior Pharmaceuticals INDV.O to create a diversified biopharmaceutical company specialized in the central nervous system
** INDV stockholders to receive one-time special cash dividend of $1.0 billion in aggregate before the deal closes; SUPN shareholders to receive 1.5401 shares of INDV per SUPN share
** New entity will be named Supernus and current CEO of SUPN, Jack Khattar will lead it
** Deal expected to close in Q4 of 2026
** Co posts Q2 revenue of $219.06 mln, beating analysts' estimates $204.96 mln - data compiled by LSEG
** As of last close, stock down 10.2% YTD
(Reporting by Anand Gopal in Bengaluru)
Recent news on Indivior Pharmaceuticals
See all newsIndivior Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Supernus soars on Indivior merger, Q2 revenue beat
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Indivior Pharmaceuticals beats Q2 revenue on Sublocade growth, raises FY guidance
Indivior Pharmaceuticals Q1 revenue rises 19%, beats estimates